Clinical Practice Recommendations on Kidney Management in Methylmalonic Acidemia: an Expert Consensus Statement From ERKNet and MetabERN
Methylmalonic acidemias (MMAs) are rare inherited metabolic diseases with multiorgan involvement. Chronic kidney disease (CKD) is a common complication, leading to kidney failure, dialysis, and kidney transplantation (KT). The objective of these guidelines was to develop clinical practice recommendations focusing on specific aspects of the kidney management of this disease. Development of these clinical practice recommendations is an initiative of the European Reference Network for Rare Kidney Diseases in collaboration with the European Reference Network for Hereditary Metabolic Disorders and included pediatric and adult nephrologists, metabolic specialists, as well as liver and kidney transplant specialists. CKD has become a significant clinical issue that requires specific follow-up in both pediatric and adult departments. Creatinine-based formulae significantly overestimate kidney function and the estimation of estimated glomerular filtration rate (eGFR) is more accurate using cystatin C. Besides usual kidney indications, acute dialysis may be required in emergency in case of acute metabolic decompensation to clear metabolic toxins. Long-term dialysis may be initiated for clearance of toxic metabolites. Long hours on hemodialysis (HD) and/or daily dialysis are required. The indications for transplantation in MMA are a high rate of metabolic decompensations, a high burden of disease and difficult metabolic control. Transplantation is also indicated in case of long-term complications. Combined liver-kidney transplantation (LKT) should be preferred in patients with MMA with CKD. Possible calcineurin inhibitors (CNIs) induced neurotoxicity was described in patients with MMA requiring immunosuppressive treatment monitoring and adaptation. Overall, 13 statements were produced to provide guidance on the management of CKD, dialysis, and transplantation in pediatric and adult patients with MMA.
Authors
- Manuel Schiff (ORCID: https://orcid.org/0000-0001-8272-232X)
- Gema Ariceta (ORCID: https://orcid.org/0000-0003-1763-1098)
- Jun Oh (ORCID: https://orcid.org/0000-0003-1846-675X)
- Marco Spada (ORCID: https://orcid.org/0000-0003-0796-6847)
- Miriam Zacchia (ORCID: https://orcid.org/0000-0003-0376-2783)
- Rukshana Shroff (ORCID: https://orcid.org/0000-0001-8501-1072)
- Roberta Taurisano
- Laurène Dehoux
- Aude Servais (ORCID: https://orcid.org/0000-0002-8165-8212)
- Jelena Stojanović (ORCID: https://orcid.org/0000-0001-9887-9081)
- Anaïs Brassier (ORCID: https://orcid.org/0000-0002-9528-3546)
- Carlo Dionisi‐Vici (ORCID: https://orcid.org/0000-0002-0007-3379)
- Stefan Kölker (ORCID: https://orcid.org/0000-0001-5188-9477)
- Friederike Hörster
- Dello Strologo
Institutions
- Universitat Autònoma de Barcelona (ES)
- Hôpital Necker-Enfants Malades (FR)
- Inserm (FR)
- Universität Hamburg (DE)
- Institut Necker Enfants Malades (FR)
- University Medical Center Hamburg-Eppendorf (DE)
- Bambino Gesù Children's Hospital (IT)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1016/j.ekir.2024.09.002
- Citations
- 2
- Primary Topic
- Metabolism and Genetic Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.76
Funders
- Amsterdam University Medical Centers
- Ospedale Pediatrico Bambino Gesù
- European Commission
- Institut National de la Santé et de la Recherche Médicale
- Universiteit Gent
- Universitair Medisch Centrum Groningen
- Radboud Universitair Medisch Centrum
- Assistance publique-Hôpitaux de Paris
- European Rare Kidney Disease Reference Network
- Universitaire Ziekenhuizen Leuven, KU Leuven